Roivant Sciences Financial Ratios
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
35.44+1.23 (+3.60%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Roivant Sciences ratio analysis
Roivant Sciences earned a net margin of -3629.2% in FY 2025, down from -592.0% a year earlier. Return on equity reached -6.6%, meaning Roivant Sciences generated -0.07 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Roivant Sciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | 2.02 | — | — | — |
| Price / sales | 2,379.80 | 236.20 | 252.36 | 166.84 | 58.63 | 258.96 |
| Price / book | 4.34 | 1.46 | 1.38 | 4.54 | 1.96 | 3.43 |
| Operating margin | -6,235.7% | -3,453.3% | 13,746.9% | -2,875.9% | -2,444.8% | -4,500.5% |
| Net margin | -3,629.2% | -592.0% | 13,294.2% | -3,200.2% | -1,528.9% | -3,400.9% |
| Free cash flow margin | -9,183.5% | -2,905.2% | -2,343.6% | -2,715.1% | -1,257.4% | -2,344.8% |
| Return on equity (ROE) | -6.6% | -3.7% | 72.9% | -87.2% | -51.0% | -45.0% |
| Return on assets (ROA) | -5.3% | -3.2% | 60.2% | -42.2% | -32.7% | -31.2% |
| Debt / equity | — | — | 0.07 | 0.36 | 0.13 | 0.09 |
| Current ratio | 18.37 | 33.47 | 25.24 | 6.60 | 11.64 | 9.99 |
| Revenue growth | -71.6% | -11.2% | 3.8% | -43.0% | 132.3% | — |
| EPS growth | — | -104.6% | — | — | — | — |